Evidence map›Paper›PMID 39181447›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2024

The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.

Hedy L Kindler, Adam Rosenthal, Dorothy J Giroux, Anna K Nowak, Andrea Billè, Ritu R Gill, Harvey Pass, David Rice, Robert T Ripley, Andrea Wolf and 4 more

Abstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hedy L KindlerDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois. Electronic address: hkindler@bsd.uchicago.edu.
Adam RosenthalCancer Research And Biostatistics, Seattle, Washington.
Dorothy J GirouxCancer Research And Biostatistics, Seattle, Washington.
Anna K NowakNational Centre for Asbestos Related Diseases, Medical School, University of Western Australia, Crawley, Australia.
Andrea BillèThoracic Surgery, Guy's Hospital, London, United Kingdom.
Ritu R GillDepartment of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Harvey PassThoracic Surgery, NYU Langone Medical Center, New York, New York.
David RiceThoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert T RipleyDepartment of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
Andrea WolfDepartment of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Kevin G BlythSchool of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Susanna CedresThoracic Tumors Unit, University Hospital Vall d'Hebron, Barcelona, Spain.
Valerie RuschThoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014599
6 · The paper itself

Abstract

introductionThe International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.

methodsCases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.

resultsOf 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (p < 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, p = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, p = 0.45).

conclusionsThis evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.

Indexed as

Lung NeoplasmsMesotheliomaNeoplasm StagingPleural NeoplasmsAgedFemaleHumansMaleMesothelioma, MalignantMiddle AgedPrognosisSurvival RateM componentMesotheliomaStagingTNM classification

Identifiers

PMID39181447
PMCPMC13248998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.